Gene expression of prostate-specific membrane antigen ( FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors
Highlights • Combination systemic therapies (STs) including immuno-oncologic (IO) and VEGF-inhibiting (VEGFi) agents, predominantly tyrosine kinase inhibitors (TKI), have become the standard of care for metastatic clear cell carcinoma. •…